All In Biotech

NDA 205919 · Nova Labs LTD

Purixan

Mercaptopurine · Oral

Orphan

Last checked: Nov 20, 2026Latest source record: Jul 16, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Apr 28, 2014

Approved uses

1

Original approval plus efficacy supplements

Registered trials

396

144 Phase 3, 58 recruiting

FAERS reports

18,153

15,651 serious, 1,997 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 20, 2026.

MERCAPTOPURINE is a nucleoside metabolic inhibitor indicated for the treatment of patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen. ( 1.1 ) 1.1 Acute Lymphoblastic Leukemia MERCAPTOPURINE is indicated for the treatment of patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Mechanism: Mercaptopurine is a purine analog that undergoes intracellular transport and activation to form metabolites including thioguanine nucleotides (TGNs). Incorporation of TGNs into DNA or RNA results in cell-cycle arrest and cell death. TGNs and other mercaptopurine metabolites are also inhibitors of de novo purine synthesis and purine nucleotide interconversions. Mercaptopurine was cytotoxic to proliferating cancer cells in vitro and had antitumor activity in mouse tumor models. It is not known which of the biochemical effects of mercaptopurine and its metabolites are directly or predominantly...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 28, 2014 Original approval · Type 5 - New Formulation or New Manufacturer OrphanLabelLetterReview
1 products under this application
  • PURIXAN · MERCAPTOPURINE 20MG/ML · SUSPENSION, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Mercaptopurine" as an intervention, any sponsor and status, largest first.

All 396 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • febrile neutropenia1,952
  • off label use1,399
  • pyrexia1,229
  • drug ineffective1,122
  • nausea825
  • vomiting796
  • abdominal pain724
  • diarrhoea721
  • neutropenia627
  • headache614
  • fatigue567
  • pneumonia541

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004192
2005151
2006163
2007223
2008272
2009478
2010554
2011643
2012830
2013465
2014765
2015817
2016928
20171,156
20181,319
20191,277
20201,187
20211,379
20221,435
20231,287
20241,190
2025859
2026583

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Purixan (Mercaptopurine)

2024 spending

$62K

Beneficiaries

n/a

34 claims

Per beneficiary

n/a

$14.53 per unit

View as table
YearSpending
2020$61,435
2021$125,467
2022$116,167
2023$58,605
2024$61,734

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 475 on PubMed

Sponsor: Nova Labs LTD

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.